# US 9,040,496 B2 · Reduction of ALMS1 gene expression or inhibition of altröm protein to induce cardiomyocyte proliferation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,040,496 B2
- Document ID: US9040496B2
- Status: Granted
- Kind: B2
- Application number: 14/089,833
- Filed: 2013-11-26
- Published: 2014-06-26
- Granted: 2015-05-26
- Earliest claimed: 2012-11-27
- Assignees: The Johns Hopkins University
- Applicants: The Johns Hopkins University
- Inventors: Daniel Philip Judge; Peter Andersen; Lincoln Takura Shenje
- Web page: https://patentgrep.com/patent/US9040496B2

## CPC

- C12N 15/1136: {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to the field of cardiology. More specifically, the present invention provides methods and compositions for inducing proliferation of cardiomyocytes. In a specific embodiment, a method for inducing proliferation of cardiomyocytes comprises the step of administering an effective amount of an ALMS1 inhibitor.

## Claims

### Claim 1

A method for inducing proliferation of cardiomyocytes comprising the step of administering an effective amount of an Alstrom syndrome 1 protein (ALMS1) inhibitor, wherein the ALMS1 inhibitor is an antisense oligonucleotide.

### Claim 2

A method for inducing proliferation of cardiomvocytes in a patient suffering from heart failure, cardiomyopathy, congenital heart disease or cardiac injury comprising the step of administering to the patient a therapeutically effective amount of an ALMS1 inhibitor, wherein the ALMS1 inhibitor is an siRNA, shRNA or an antisense oligonucleotide.

### Claim 3

A method for treating heart failure, cardiomyopathy, congenital heart disease or cardiac injury in a patient comprising the step of administering to the patient a therapeutically effective amount of an ALMS1 inhibitor, wherein the ALMS1 inhibitor is an siRNA, and further wherein the ALMS1 inhibitor inhibits ALMS1 expression and/or activity and induces proliferation of cardiomyocytes.

### Claim 4

A method for treating heart failure, cardiomyopathy, congenital heart disease or cardiac injury in a patient comprising the step of administering to the patient a therapeutically effective amount of an ALMS1 inhibitor, wherein the ALMS1 inhibitor is shRNA, and further wherein the ALMS1 inhibitor inhibits ALMS1 expression and/or activity and induces proliferation of cardiomyocytes.

### Claim 5

A method for treating heart failure, cardiomyopathy, congenital heart disease or cardiac injury in a patient comprising the step of administering to the patient a therapeutically effective amount of an ALMS1 inhibitor, wherein the ALMS1 inhibitor is an antisense oligonucleotide, and further wherein the ALMS1 inhibitor inhibits ALMS1 expression and/or activity and induces proliferation of cardiomyocytes.

### Claim 6

A method for inducing proliferation of cardiomyocytes comprising the step of administering an effective amount of an siRNA or shRNA inhibitor of the expression of the ALMS1 gene to result in RNA interference.